[1]Naughton P, Healy M, Enright F, et al. Infectious mononucleosis: diagnosis and clinical interpretation[J]. Br J Biomed Sci, 2021, 78:107-116. [2]Abe N, Fujieda Y. Chronic active Epstein-Barr virus infection[J]. Blood, 2020, 136:2090.doi:10.1182/blood.2020008157. [3]Shi J, Chu C, Yu M, et al. Clinical warning of hemophagocytic syndrome caused by Epstein-Barr virus[J]. Ital J Pediatr, 2021, 47:3. doi:10.1186/s13052-020-00949-7. [4]Hue SS, Oon ML, Wang S, et al. Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach[J]. Pathology, 2020, 52:111-127. [5]Auerbach A, Aguilera NS. Epstein-Barr virus (EBV)-associated lymphoid lesions of the head and neck[J]. Semin Diagn Pathol, 2015, 32:12-22. [6]Murata T, Tsurumi T. Switching of EBV cycles between latent and lytic states[J]. Rev Med Virol, 2014, 24:142-153. [7]Guo R, Gewurz BE. Epigenetic control of the Epstein-Barr lifecycle[J]. Curr Opin Virol, 2022, 52:78-88. [8]Zuo L, Yue W, Du S, et al. An update: Epstein-Barr virus and immune evasion via microRNA regulation[J]. Virol Sin, 2017, 32:175-187. [9] Lista MJ, Martins RP, Billant O, et al. Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA[J]. Nat Commun, 2017, 8:16043.doi:10.1038/ncomms16043. [10] Münz C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis[J]. Nat Rev Microbiol, 2019, 17:691-700. [11]Praest P, Luteijn RD, Brak-Boer IGJ, et al. The influence of TAP1 and TAP2 gene polymorphisms on TAP function and its inhibition by viral immune evasion proteins[J]. Mol Immunol, 2018, 101:55-64. [12]Li Q, Cohen JI. Epstein-Barr Virus and the human leukocyte antigen complex[J]. Curr Clin Microbiol Rep, 2019, 6:175-181. |